Mucin production in airway epithelial cells

Mucin production in airway epithelial cells is a regulated biological process in which specialized secretory cells, such as goblet cells and submucosal gland cells, synthesize and secrete large, gel-forming glycoproteins called mucins (primarily MUC5AC and MUC5B)[1][2][3][4][5]. These mucins hydrate to form mucus, which lines and protects the airway epithelium by trapping inhaled particulates, pathogens, and facilitating their removal via mucociliary clearance. Under homeostasis, mucin secretion occurs at a low basal rate, with potential for rapid stimulation (e.g., by irritants or infection)[1][3][5]. Both underproduction (leading to impaired defense) and overproduction/hypersecretion (leading to airway obstruction and chronic disease) are associated with significant respiratory pathology, including asthma, COPD, and cystic fibrosis[4][5]. Mucin exocytosis is controlled by a complex machinery involving SNARE proteins, MARCKS, Munc13-2, and calcium-mediated signaling[1][5]. Therapeutic intervention targets mucin production or secretion mainly in disease states characterized by mucus hypersecretion, but excessive suppression can be detrimental to innate lung defense. Key limitation: "Mucus production in airways" is not a single molecular target, but rather a complex biological process involving multiple protein classes (mucins, regulatory proteins, enzymes) and cell types[1][2][3][4][5]. For structured drug-target or receptor databases, each component (e.g., "Mucin 5AC," "Mucin 5B," or specific receptors like "P2Y2 receptor") should be reviewed individually for target status. If a database entry requires a specific molecular entity, replace "Mucus production in airways" with the principal proteins involved, such as "Mucin 5AC" or "Mucin 5B"[2][3]. "Mucus production in airways" is best classified as a physiological process, not a single target.

Other names

Airway mucus productionAirway mucin secretionAirway mucus secretion

Anti-inflammatory agents reduce goblet cell hyperplasia and mucin gene expression; Mucolytics decrease mucus viscosity; Proteolytic enzymes such as DNase break down extracellular DNA, decreasing mucus viscosity; Bronchodilators improve mucociliary clearance by enhancing ciliary function.